ibandronic acid has been researched along with simvastatin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Skoglund, B | 1 |
| Gerner, C; Grunt, T; Haider, F; Karlic, H; Proestling, K; Thaler, R; Varga, F | 1 |
1 review(s) available for ibandronic acid and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for ibandronic acid and simvastatin
| Article | Year |
|---|---|
Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Coated Materials, Biocompatible; Diphosphonates; Disease Models, Animal; Femoral Fractures; Fracture Healing; Fractures, Bone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Injections, Subcutaneous; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Rats; Rats, Sprague-Dawley; Simvastatin | 2007 |
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Epigenesis, Genetic; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Mevalonic Acid; MicroRNAs; NADP; Neoplasms; Protein Processing, Post-Translational; Simvastatin; Vitamin D | 2015 |